65 /100
HIGH RISK
Score updated Jul 13, 2026

ABVC — ABVC BioPharma, Inc. Dilution Risk Tracker

Track ABVC dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ABVC — Get alerts when the score changes →

As of July 13, 2026, ABVC BioPharma, Inc. (ABVC) has a DilutionWatch DilutionScore of 65/100, rated HIGH dilution risk. ABVC BioPharma, Inc. has a market capitalization of $36.66M, 26.00M shares outstanding, 15 institutional holders tracked. Key dilution vectors include 500.0K outstanding warrants, approximately 1 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
95
📊 Float Risk
27
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
44%
💰 Capital Raise 55%
• Critical: only 0.7 months cash remaining
🔄 Reverse Split 45%
• 50-day avg $1.17 approaching $1 threshold
• Only 1 months cash — financial pressure
🔁 Convertible Conversion 15%
• Convertible debt present: 6.1% potential dilution
🔔 Track ABVC — Get forecast alerts →

💹 Market Data

Market Cap$36.66M
Shares Outstanding26.00M
Float20.44M
Cash$202.5K
Debt$213.1K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 16.7% shares (2026Q1 vs prior)
15 institutional holders · 1.02M shares
#1 VANGUARD CAPITAL MANAGEMENT LLC 381.1K shares
#2 GEODE CAPITAL MANAGEMENT, LLC 221.2K shares
#3 VANGUARD FIDUCIARY TRUST CO 97.4K shares
+ 12 more holders Sign up free to view →

📉 Short Interest

Short Interest366.7K
Days to Cover2.1
% of Float1.8%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
xbrl XBRL CONVERTIBLE Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for ABVC Shareholders

ABVC BioPharma, Inc. (ABVC) has a DilutionScore of 65/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 13, 2026, updated from SEC EDGAR data.

DilutionWatch tracks 500,000 outstanding warrants for ABVC. Warrants become dilutive when exercised — converting to common shares at the strike price. Warrants near or in-the-money deserve particular attention since exercise can add materially to the outstanding share count within a short window. Cash runway is a key watch item: ABVC has approximately 1 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for ABVC in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for ABVC alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Warrants Explained →
Track ABVC Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ABVC — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for ABVC
📊 ABVC FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 ABVC Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.